Murray Passo to Antirheumatic Agents
This is a "connection" page, showing publications Murray Passo has written about Antirheumatic Agents.
Connection Strength
1.679
-
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
Score: 0.154
-
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):717-734.
Score: 0.154
-
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019 06; 71(6):846-863.
Score: 0.154
-
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
Score: 0.152
-
Use of methotrexate in children. Bull Rheum Dis. 1998 Aug; 47(5):1-5.
Score: 0.147
-
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in?Children With Polyarticular Forms of Juvenile Idiopathic?Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
Score: 0.146
-
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2018 04; 70(4):594-605.
Score: 0.142
-
The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997 Dec; 40(12):2226-34.
Score: 0.140
-
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996 Nov; 129(5):630-2.
Score: 0.130
-
Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008 Aug; 14(4):195-201.
Score: 0.073
-
Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007 Aug 15; 57(6):1000-6.
Score: 0.069
-
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct; 24(5):599-605.
Score: 0.064
-
Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Curr Probl Pediatr Adolesc Health Care. 2006 Mar; 36(3):97-103.
Score: 0.062
-
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003 Feb; 30(2):394-400.
Score: 0.050
-
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50.
Score: 0.034
-
Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec; 21(12):2353-8.
Score: 0.007